



**World Health
Organization**

Initiative for Vaccine Research, Global Influenza Programme

**5th WHO Meeting on Evaluation of Pandemic Influenza Prototype Vaccines in
Clinical Trials**

Meeting venue: WHO/HQ, Salle A, Main Building

Geneva

12-13 February 2009

DRAFT AGENDA

Chair: Dr Linda Lambert

Rapporteur: Dr Frederick Hayden

Thursday, 12 February

14:30	Registration and coffee	
15:00	Opening and welcome	Dr Marie-Paule Kieny
	Presentation of participants	
	Administrative information	Dr Laszlo Palkonyay
	<u>Clinical trials</u>	
	<i>Egg derived inactivated vaccines</i>	
15:20	Further studies on an alum-adjuvanted H5N1 candidate vaccine, CSL Australia	Dr Terry Nolan
15:40	Update on H5N1 vaccine, Sinovac Biotech., China	Dr Yong Zou
16:00	Update on clinical results of recent pandemic influenza trials Novartis	Dr Nicola Groth
16:20	Update on H5N1 vaccine, Sanofi Pasteur	Dr Martine Denis
16:40	Update on H5N1 vaccine, GSK Biologicals	Dr Emmanuel Hanon

17:00	Update from the NIH on inactivated vaccine trials	Dr Linda Lambert
17:20	Discussion	
17:40	End of the first day session	
18:00 - 19:30	Reception	

Friday 13 February

	<i>Cell derived inactivated vaccines</i>	
09:00	Update on H5N1 vaccine, Baxter	Dr Otfried Kistner
09:20	Safety and immunogenicity of the cell-derived whole virus H5N1 vaccine in the phase 1 trial, Vabiotech, Vietnam	Dr Nguyen Thu Van
09:40	Discussion on cell-derived inactivated vaccine	
	<i>Live attenuated vaccines</i>	
10:00	Live attenuated pandemic influenza vaccines: preclinical data	Dr Catherine Luke
10:20	Live attenuated pandemic influenza H2N2 and H6N1 vaccines: clinical data	Dr Kawsar Talaat
10:40	Coffee Break	
11:10	H5N2 in Phase II clinical trials, Microgen and Inst. Exp. Medicine, Russia	Vitaliy Zverev
11:30	Discussion on live attenuated vaccines	
	<i>Vaccines developed using new technologies</i>	
11:50	Evaluation of DeINS1 intranasal H5N1 vaccine	Dr Julia Romanova
12:10	Safety and immunogenicity of an H5N1 (A/Indonesia/05/2005) virus-like particle vaccine candidate, Novavax, USA	Dr Penny Heaton

12:30	Development of split virosomal pre-pandemic influenza vaccine adjuvanted with Aluminum Hydroxide, Microgen, Russia	Dr Igor Krasilnikov
12:50	Lunch	
14:00	Phase 1 safety and immunogenicity results of Vaxfectin-formulated influenza H5 DNA vaccines, Vical, USA	Dr Larry Smith
14:20	Phase 1 clinical trials of M2e vaccine, Sanofi Pasteur	Dr Patricia Londono-Arcila
14:40	Phase I/II clinical trials of rHA protein of H5N1, UMN Pharma, Japan.	Dr Shu-Ichi Kanazashi
15:00	Discussion on new generation vaccines	
	<u>Regulatory and other relevant issues</u>	
15:20	Results of Different H5N1 Vaccine - Adjuvant Studies	Dr Robin Robinson
15:40	Update on development of international standards for H5N1 antibodies	Dr John Wood
16:00	Coffee break	
16.20	Novel methods for assessment of immunogenicity of pandemic vaccines	Katja Hoschler
16:40	Progress in regulatory preparedness	Dr David Wood
17:00	Discussion on regulatory and related issues	
	<u>General concluding session</u>	
17:20	General discussion	
17:45	Conclusions	Dr Linda Lambert
18:00	End of the meeting	